COMMUNIQUÉS West-GlobeNewswire

Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101
28/08/2018
Cancer Discovery Features Reports of Early Clinical Trials of SD-101 in Lymphoma and Advanced Melanoma BERKELEY, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced [...]
Bhang Accelerates Growth with New Headquarters in Miami
28/08/2018
Recent Real Estate Deal Enables Bhang Corporation to Significantly Expand Operations MIAMI, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Bhang Corporation , the award-winning company famous for its Bhang-branded cannabis edibles, [...]
G1 Therapeutics to Present at H.C. Wainwright Investment Conference on September 5, 2018
28/08/2018
RESEARCH TRIANGLE PARK, N.C., Aug. 28, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Buck Phillips, Chief Financial Officer and Senior Vice [...]
Financial Calendar 2018/19
28/08/2018
Company Announcement No. 13/2018 Attachment No 13 2018_Financial Calendar 20182019
Transactions in relation to share buyback program
28/08/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Aino Health AB (publ): Aino Health signs agreement with Sjuksyrra AB
28/08/2018
28 August 2018 Because of increased demand for Aino Health's offering and to continue increasing scalability, Aino Health has signed an agreement with Sjuksyrra AB. Sjuksyrra AB is a staffing company in health care [...]
GENFIT: Major Milestone achieved with full recruitment of the Phase 2 trial evaluating elafibranor in PBC
28/08/2018
GENFIT: Major Milestone achieved with full recruitment of the Phase 2 trial evaluating elafibranor in PBC Final patient randomized in a Phase 2a clinical trial evaluating efficacy and safety of elafibranor in PBC ( [...]
GENFIT : étape importante franchie avec la fin du recrutement des patients de l'essai de Phase 2 évaluant elafibranor dans la PBC
28/08/2018
GENFIT : étape importante franchie avec la fin du recrutement des patients de l'essai de Phase 2 évaluant elafibranor dans la PBC Randomisation du dernier patient de l'essai de phase 2a évaluant l'efficacité et l' [...]
GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of Epileptology
28/08/2018
VIENNA, Austria, Aug. 28, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid prescription medicines, [...]
ObsEva SA to Participate in September Investor Conferences
28/08/2018
Geneva, Switzerland and Boston, MA – August 28, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
MDxHealth (R): SelectMDx Cost-effective in Four European Countries
28/08/2018
NEWS RELEASE REGULATED INFORMATION Potential healthcare cost savings in France, Germany, Italy and Spain of over €300 million IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CEST, 28 August 2018 - MDxHealth SA (Euronext: MDXH. [...]
MDxHealth (R) :
28/08/2018
MDxHealth (R): SelectMDx Cost-effective in Four European Countries
28/08/2018
NEWS RELEASE REGULATED INFORMATION Cost savings for healthcare providers in France, Germany, Italy and Spain of over €300 million IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CEST, 28 August 2018 - MDxHealth SA (Euronext: [...]
MDxHealth (R) : SelectMDx : rapport coût-effectivité positif dans quatre pays européens
28/08/2018
COMMUNIQUÉ DE PRESSE INFORMATIONS RÉGLEMENTÉES Une économie potentielle de plus de 300 millions d'euros sur les soins de santé en France, en Allemagne, en Italie et en Espagne IRVINE, CA, et HERSTAL, BELGIQUE - 07:00 [...]
Biocartis Group NV: Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
28/08/2018
PRESS RELEASE : 28 August 2018, 07:00 CEST Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy Mechelen, Belgium, 28 August 2018 [...]
Kiadis Pharma to attend upcoming investor conferences in September 2018
28/08/2018
Kiadis Pharma to attend upcoming investor conferences in September 2018 Amsterdam, The Netherlands, August 28, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a [...]
Orphazyme announces Interim Report First Half 2018
28/08/2018
Orphazyme A/S Company announcement No. 11/2018 Company Registration No. 32266355 The first part of 2018 has taken Orphazyme further along the path of bringing arimoclomol to rare disease patients in great need of new [...]
Wright Medical Group N.V. Announces Pricing of Public Offering of Ordinary Shares
28/08/2018
AMSTERDAM, The Netherlands, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) today announced the pricing of its previously announced registered underwritten public offering of 18,248,932 of its [...]
EB Research Partnership and EB Research Foundation Join Forces to Advance Breakthroughs in Epidermolysis Bullosa Research
28/08/2018
The two leading global nonprofits announce a partnership to combine resources to heal EB NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), based in New York, and Australian-based EB Research [...]

Pages